NCT04551989 - Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

December 11, 2020

Primary Completion Date

April 27, 2023

Study Completion Date

April 27, 2023

Conditions

Churg-Strauss SyndromeEosinophilic Granulomatosis With Polyangiitis

Trial Locations (34)

489-8642

GSK Investigational Site, Aichi

371-8511

GSK Investigational Site, Gunma

653-0013

GSK Investigational Site, Hyōgo

670-8520

GSK Investigational Site, Hyōgo

674-0063

GSK Investigational Site, Hyōgo

675-8611

GSK Investigational Site, Hyōgo

920-8530

GSK Investigational Site, Ishikawa

923-8560

GSK Investigational Site, Ishikawa

216-8511

GSK Investigational Site, Kanagawa

241-0801

GSK Investigational Site, Kanagawa

241-0811

GSK Investigational Site, Kanagawa

252-0392

GSK Investigational Site, Kanagawa

780-8522

GSK Investigational Site, Kochi

510-8567

GSK Investigational Site, Mie

511-0061

GSK Investigational Site, Mie

980-8574

GSK Investigational Site, Miyagi

533-0024

GSK Investigational Site, Osaka

534-0021

GSK Investigational Site, Osaka

350-8550

GSK Investigational Site, Saitama

520-2192

GSK Investigational Site, Shiga

430-8525

GSK Investigational Site, Shizuoka